山东大学耳鼻喉眼学报 ›› 2023, Vol. 37 ›› Issue (3): 118-124.doi: 10.6040/j.issn.1673-3770.0.2022.032

• 综述 • 上一篇    

中心性浆液性脉络膜视网膜病变的发病机制与治疗研究进展

李璐,赵杰,赵博军   

  1. 山东大学附属省立医院 眼科, 山东 济南 250021
  • 发布日期:2023-05-24
  • 通讯作者: 赵博军. E-mail:15168860708@163.com

Research progress on the pathogenesis and treatments of central serous chorioretinopathy

LI Lu, ZHAO Jie, ZHAO Bojun   

  1. Department of Ohthalmology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China
  • Published:2023-05-24

PDF (PC)

150

摘要： 中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy, CSC)是常见的引起视力损害的眼底疾病之一,主要表现为中心视力下降、视物显小等。A型性格、外源性使用糖皮质激素、内源性皮质醇水平升高等是CSC常见的危险因素。眼底荧光素及吲哚菁绿血管造影提示CSC可能继发于脉络膜血管通透性增高及视网膜色素上皮层功能障碍,但其病理生理学过程尚未明确,治疗方法仍无统一的金标准,目前应用最多的治疗方法是光动力疗法及视网膜激光光凝。论文回顾了关于CSC的危险因素、发病机制、病理生理学过程及治疗方法的研究进展,为临床诊疗提供新的思路。

关键词: 中心性浆液性脉络膜视网膜病变, 危险因素, 发病机制, 病理生理学, 治疗方法

Abstract: Central serous chorioretinopathy(CSC), one of the most common causes of visual impairment among fundus oculi diseases, typically presents with central vision loss and micropsia. Having a type A personality, administration of exogenous glucocorticoids, and endogenous hypercortisolism have been recognized as risk factors for CSC. Fundus fluorescein angiography and indocyanine green angiography have shown that CSC may be secondary to choroidal vascular hyperpermeability and retinal pigment epithelial dysfunction. However, its exact pathophysiology and management remain unknown. Photodynamic and laser photocoagulation have been used as managements for patients with CSC. This article provides an overview of CSC's risk factors, pathogenesis, pathophysiology and treatments.

Key words: Central serous chorioretinopathy, Risk factors, Pathogenesis, Pathophysiology, Treatments

中图分类号: 

  • R774.5
[1] Liu B, Deng T, Zhang JJ. Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis[J]. Retina, 2016, 36(1): 9-19. doi:10.1097/IAE.0000000000000837
[2] Manayath GJ, Arora S, Parikh H, et al. Is myopia a protective factor against central serous chorioretinopathy? [J]. Int J Ophthalmol, 2016, 9(2): 266-270. doi:10.18240/ijo.2016.02.16
[3] Tewari HK, Gadia R, Kumar D, et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study[J]. Invest Ophthalmol Vis Sci, 2006, 47(8): 3474-3478. doi:10.1167/iovs.05-1246
[4] 张新媛, 赖旭佑. 关注黄斑区肥厚型脉络膜疾病谱的概念及研究[J]. 中华实验眼科杂志, 2017, 35(5): 385-390. doi:10.3760/cma.j.issn.2095-0160.2017.05.001 ZHANG Xinyuan, LAI Xuyou. Paying attention to the concept and research of pachychoroid disease spectrum[J]. Chinese Journal of Experimental Ophthalmology, 2017, 35(5): 385-390. doi:10.3760/cma.j.issn.2095-0160.2017.05.001
[5] 王海燕, 王雨生. 值得关注的肥厚型脉络膜病变[J]. 眼科新进展, 2020, 40(3): 201-205. doi:10.13389/j.cnki.rao.2020.0048 WANG Haiyan, WANG Yusheng. Pachychoroidopathy: a novel subject deserving of deep exploration[J]. Recent Advances in Ophthalmology, 2020, 40(3): 201-205. doi:10.13389/j.cnki.rao.2020.0048
[6] Yannuzzi LA. Type A behavior and central serous chorioretinopathy[J]. Trans Am Ophthalmol Soc, 1986, 84: 799-845.
[7] Sibayan SA, Kobuch K, Spiegel D, et al. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2000, 238(6): 515-519. doi:10.1007/pl00007893
[8] Kim YK, Woo SJ, Park KH, et al. Association of central serous chorioretinopathy with psychosocial factors is dependent on its phase and subtype[J]. Korean J Ophthalmol, 2018, 32(4): 281-289. doi:10.3341/kjo.2017.0144
[9] Chen J, Wang ZZ, Zhang S, et al. Does mineralocorticoid receptor play a vital role in the development of depressive disorder? [J]. Life Sci, 2016, 152: 76-81. doi:10.1016/j.lfs.2016.03.022
[10] Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis[J]. Prog Retin Eye Res, 2015, 48: 82-118. doi:10.1016/j.preteyeres.2015.05.003
[11] Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy[J]. J Clin Invest, 2012, 122(7): 2672-2679. doi:10.1172/JCI61427
[12] Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy[J]. Ophthalmologica, 2001, 215(3): 183-187. doi:10.1159/000050855
[13] van Dijk EHC, Schellevis RL, Breukink MB, et al. Familial central serous chorioretinopathy[J]. Retina, 2019, 39(2): 398-407. doi:10.1097/IAE.0000000000001966
[14] Giannopoulos K, Gazouli M, Chatzistefanou K, et al. The genetic background of central serous chorioretinopathy: a review on central serous chorioretinopathy genes[J]. J Genomics, 2021, 9: 10-19. doi:10.7150/jgen.55545
[15] Kaye R, Chandra S, Sheth J, et al. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities[J]. Prog Retin Eye Res, 2020, 79: 100865. doi:10.1016/j.preteyeres.2020.100865
[16] Mohabati D, Schellevis RL, van Dijk EHC, et al. Genetic risk factors in acute central serous chorioretinopathy[J]. Retina, 2019, 39(12): 2303-2310. doi:10.1097/IAE.0000000000002333
[17] Schellevis RL, van Dijk EHC, Breukink MB, et al. Exome sequencing in families with chronic central serous chorioretinopathy[J]. Mol Genet Genomic Med, 2019, 7(4): e00576. doi:10.1002/mgg3.576
[18] Nicholson BP, Atchison E, Idris AA, et al. Central serous chorioretinopathy and glucocorticoids: an update on evidence for association[J]. Surv Ophthalmol, 2018, 63(1): 1-8. doi:10.1016/j.survophthal.2017.06.008
[19] Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy[J]. Am J Ophthalmol, 1999, 128(1): 63-68. doi:10.1016/s0002-9394(99)00075-6
[20] Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy[J]. Ophthalmology, 2003, 110(4): 698-703. doi:10.1016/S0161-6420(02)01975-9
[21] Abalem MF, Machado MC, Santos HN, et al. Choroidal and retinal abnormalities by optical coherence tomography in endogenous Cushing's syndrome[J]. Front Endocrinol(Lausanne), 2016, 7: 154. doi:10.3389/fendo.2016.00154
[22] 王维亚. 中心性浆液性脉络膜视网膜病变中糖皮质激素、儿茶酚胺等的浓度变化[J]. 医学理论与实践, 2007, 20(10): 1185-1186. doi:10.19381/j.issn.1001-7585.2007.10.054
[23] Xu H, Huang LZ, Jin EZ, et al. Plasma metabolomic profiling of central serous chorioretinopathy[J]. Exp Eye Res, 2021, 203: 108401. doi:10.1016/j.exer.2020.108401
[24] Tewari HK, Gadia R, Kumar D, et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study[J]. Invest Ophthalmol Vis Sci, 2006, 47(8): 3474-3478. doi:10.1167/iovs.05-1246
[25] Chung YR, Kim JW, Kim SW, et al. Choroidal thickness in patients with central serous chorioretinopathy[J]. Retina, 2016, 36(9): 1652-1657. doi:10.1097/iae.0000000000000998
[26] Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study[J]. Ophthalmology, 2004, 111(2): 244-249. doi:10.1016/j.ophtha.2003.09.024
[27] Imanaga N, Terao N, Nakamine S, et al. Scleral thickness in central serous chorioretinopathy[J]. Ophthalmol Retina, 2021, 5(3): 285-291. doi:10.1016/j.oret.2020.07.011
[28] Ersoz MG, Arf S, Hocaoglu M, et al. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients[J]. Br J Ophthalmol, 2019, 103(6): 725-729. doi:10.1136/bjophthalmol-2018-312431
[29] 尤冉, 郭笑霄, 陈曦, 等. 高度近视患者视网膜和脉络膜形态结构研究[J]. 临床和实验医学杂志, 2018, 17(22): 2396-2400. doi:10.3969/j.issn.1671-4695.2018.22.013 YOU Ran, GUO Xiaoxiao, CHEN Xi, et al. Retinal and choroidal morphology in 32 patients with high myopia[J]. Journal of Clinical and Experimental Medicine, 2018, 17(22): 2396-2400. doi:10.3969/j.issn.1671-4695.2018.22.013
[30] Cilo glu E, Unal F, Dogan NC. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(6): 1111-1116. doi:10.1007/s00417-018-3985-x
[31] Wickham LA, Gao J, Toda I, et al. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye[J]. Acta Ophthalmol Scand, 2000, 78(2): 146-153. doi:10.1034/j.1600-0420.2000.078002146.x
[32] Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues[J]. Br J Ophthalmol, 2000, 84(1): 76-84. doi:10.1136/bjo.84.1.76
[33] Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography[J]. Retina, 2011, 31(2): 332-335. doi:10.1097/IAE.0b013e3181eef0ae
[34] Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2008, 246(9): 1225-1228. doi:10.1007/s00417-008-0837-0
[35] McArdle N, Hillman D, Beilin L, et al. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study[J]. Am J Respir Crit Care Med, 2007, 175(2): 190-195. doi:10.1164/rccm.200602-270OC
[36] Geiser T, Buck F, Meyer BJ, et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome[J]. Respiration, 2002, 69(3): 229-234. doi:10.1159/000063625
[37] Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis[J]. Med Hypotheses, 2004, 63(3): 524-527. doi:10.1016/j.mehy.2004.02.020
[38] Hu J, Qu JF, Piao ZY, et al. Optical coherence tomography angiography compared with indocyanine green angiography in central serous chorioretinopathy[J]. Sci Rep, 2019, 9(1): 6149. doi:10.1038/s41598-019-42623-x
[39] Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy[J]. Br J Ophthalmol, 2003, 87(6): 709-712. doi:10.1136/bjo.87.6.709
[40] 陈桂芬, 马景学, 王长龄, 等. 中心性浆液性脉络膜视网膜病变色素上皮功能状态分析[J]. 中国实用眼科杂志, 2008, 26(11): 1255-1256. doi:10.3760/cma.j.issn.1006-4443.2008.11.030 CHEN Guifen, MA Jingxue, WANG Changling, et al. Analysis of the retinal pigment epithelium function in central serous chorioretinopathy[J]. Chinese Journal of Practical Ophthalmology, 2008, 26(11): 1255-1256. doi:10.3760/cma.j.issn.1006-4443.2008.11.030
[41] Pauleikhoff L, Agostini H, Lange C. Central serous chorioretinopathy[J]. Ophthalmologe, 2021, 118(9): 967-980. doi: 10.1007/s00347-021-01376-7
[42] Breukink MB, Mohr JK, Ossewaarde-van Norel A, et al. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol[J]. Acta Ophthalmol, 2016, 94(2): 187-197. doi:10.1111/aos.12938
[43] Pichai J, Vanchalerm B, Mansing R. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy[J]. BMC Ophthalmol, 2021, 21(1): 30. doi:10.1186/s12886-020-01796-0
[44] Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy[J]. Br J Ophthalmol, 1979, 63(10): 674-677. doi:10.1136/bjo.63.10.674
[45] Wong KH, Lau KP, Chhablani J, et al. Central serous chorioretinopathy: what we have learnt so far[J]. Acta Ophthalmol, 2016, 94(4): 321-325. doi:10.1111/aos.12779
[46] 罗清礼, 王琳, 吴海英. 激光光凝后视网膜色素上皮、Bruch膜和脉络膜超微结构改变[J]. 中华眼科杂志, 2004, 40(10): 692-695. doi:10.3760/j: issn: 0412-4081.2004.10.010 LUO Qingli, WANG Lin, WU Haiying. Ultrastructure study on the RPE, Bruch's membrane and choroid after laser photocoagulation of the Retina[J]. Chinese Journal of Ophthalmology, 2004, 40(10): 692-695. doi:10.3760/j: issn: 0412-4081.2004.10.010
[47] Lim JW, Kang SW, Kim YT, et al. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy[J]. Br J Ophthalmol, 2011, 95(4): 514-517. doi:10.1136/bjo.2010.182121
[48] 赵俊华. 中心性浆液性脉络膜视网膜病变治疗方法的研究进展[J]. 中国临床新医学, 2017, 10(8): 816-820. doi:10.3969/j.issn.1674-3806.2017.08.33 ZHAO Junhua. Research progress in the treatment of central serous chorioretinopathy[J]. Chinese Journal of New Clinical Medicine, 2017, 10(8): 816-820. doi:10.3969/j.issn.1674-3806.2017.08.33
[49] Sivaprasad S, Elagouz M, McHugh D, et al. Micropulsed diode laser therapy: evolution and clinical applications[J]. Surv Ophthalmol, 2010, 55(6): 516-530. doi:10.1016/j.survophthal.2010.02.005
[50] 廖丹, 许立帅, 戴乐, 等. 577 nm阈下微脉冲激光治疗黄斑中心凹渗漏的慢性中心性浆液性脉络膜视网膜病变[J]. 眼科新进展, 2018, 38(2): 139-142. doi:10.13389/j.cnki.rao.2018.0030 LIAO Dan, XU Lishuai, DAI Le, et al. Subthreshold micropulse yellow laser(577 nm)for chronic central serous chorioretinopathy with foveal leakage[J]. Recent Advances in Ophthalmology, 2018, 38(2): 139-142. doi:10.13389/j.cnki.rao.2018.0030
[51] 任雨馨, 赵博军. 病理性近视脉络膜新生血管的诊断与治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 157-162. doi:10.6040/j.issn.1673-3770.0.2019.545 REN Yuxin, ZHAO Bojun. Diagnosis and treatment of choroidal neovascularization in pathologic myopia[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(5): 157-162. doi:10.6040/j.issn.1673-3770.0.2019.545
[52] Ji S, Wei Y, Chen J, et al. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis[J]. Int J Clin Pharm, 2017, 39(3):514-521. doi: 10.1007/s11096-017-0460-4
[53] Song YY, Yu HY, Baek SK, et al. Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography[J]. PLoS One, 2021, 16(1): e0245342. doi:10.1371/journal.pone.0245342
[54] Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy[J]. Korean J Ophthalmol, 2010, 24(3): 155-158. doi:10.3341/kjo.2010.24.3.155
[55] Chrzszcz M, Pociej-Marciak W, Zuber-Łaskawiec K, et al. Changes in plasma VEGF and PEDF levels in patients with central serous chorioretinopathy[J]. Medicina(Kaunas), 2021, 57(10): 1063. doi:10.3390/medicina57101063
[56] Bousquet E, Dhundass M, Lejoyeux R, et al. Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous chorioretinopathy[J]. Am J Ophthalmol, 2019, 198: 80-87. doi:10.1016/j.ajo.2018.09.034
[57] Lotery A, Sivaprasad S, O'Connell A, et al. Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT[J]. Efficacy Mech Eval, 2021, 8(2): 1-82. doi:10.3310/eme08020
[58] Kurup SK, Oliver A, Emanuelli A, et al. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis[J]. Retina, 2012, 32(10): 2096-2101. doi:10.1097/IAE.0b013e31825dd281
[1] 李智林,郑洲,安韡. 12例原发性甲状腺鳞状细胞癌的临床及生存分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(1): 59-63.
[2] 肖富亮,林云,潘新良. 早期cN0 PTC预防性中央区淋巴结清扫的临床研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(1): 64-71.
[3] 李爱军,崔小梅. 白内障术前房颤人群综合路径管理现状横断面调查[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 38-44.
[4] 张礼俊, 胥然, 罗继芳, 刘国旗, 何千, 李玮, 蒋振华. 头颈肿瘤游离皮瓣修复术后皮瓣坏死及皮瓣相关并发症影响因素分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 86-90.
[5] 林海,朱莹,张维天. 慢性鼻窦炎发病中离子通道作用研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 64-70.
[6] 李佳倪,朱冬冬,孟粹达. 表观遗传学在慢性鼻窦炎伴鼻息肉发病机制中的作用[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 84-91.
[7] 韩莹莹，李延忠. 阻塞性睡眠呼吸暂停低通气综合征与亚临床动脉粥样硬化[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 126-132.
[8] 刘珊珊, 韩书婧, 王晓旭, 李艳红, 倪鑫, 张杰. 儿童细菌性脑膜炎后听力损害危险因素的系统评价与Meta分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 48-54.
[9] 王宇婷，王嘉玺. microRNA在过敏性鼻炎发病机制中的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 98-104.
[10] 向浏岚,叶远航,蒋璐云,刘洋. Tim-3在变应性鼻炎中的作用及机制研究进展[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 118-122.
[11] 朱正茹,张小兵. 高迁移率族蛋白B1与变应性鼻炎的相关性[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 123-128.
[12] 杨秀芬,尤冉,马秀梅,王康,王艳玲. 以医院为基础的中心性浆液性脉络膜视网膜病变流行病学调查及危险因素的研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 75-79.
[13] 陈东,余红,李洋,黄强,方敏. 功能性鼻内窥镜鼻窦手术粘连的潜在危险因素及其预测价值[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 87-91.
[14] 黄嘉莉杨淑荣. 变应性鼻炎中信号传导通路的研究进展[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 125-129.
[15] 郝文培, 翟华蕾, 孙晓彤, 张雅妮, 朱艳辉, 孔倩倩, 程钧, 张婷. 角膜再移植原因与植片失活的危险因素分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 134-140.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发